Whitehawk Therapeutics (NASDAQ:WHWK) Now Covered by Jones Trading

Investment analysts at Jones Trading assumed coverage on shares of Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) in a research note issued on Monday,Benzinga reports. The brokerage set a "buy" rating and a $7.00 price target on the stock. Jones Trading's price target would indicate a potential upside of 177.78% from the stock's current price.Get Whitehawk Therapeutics alerts:Several other equities analysts also recently commented on WHWK. Weiss Ratings restated a "sell (e+)" rating on shares of Whitehawk Therapeutics in a research note on Monday, December 15th. Wall Street Zen cut Whitehawk Therapeutics to a "strong sell" rating in a research note on Saturday, November 1st. Finally, Zacks Research raised Whitehawk Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, October 7th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $7.00.View Our Latest Research Report on WHWKWhitehawk Therapeutics Price PerformanceNASDAQ WHWK traded down $0.04 during trading on Monday, hitting $2.52. The stock had a trading volume of 61,327 shares, compared to its average volume of 564,378. The company has a market capitalization of $118.77 million, a P/E ratio of 18.00 and a beta of 0.38. The business's 50 day moving average is $2.29. Whitehawk Therapeutics has a twelve month low of $1.39 and a twelve month high of $3.81. Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.25. Whitehawk Therapeutics had a net margin of 99.42% and a negative return on equity of 68.32%. Institutional Trading of Whitehawk TherapeuticsSeveral institutional investors and hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC acquired a new stake in shares of Whitehawk Therapeutics during the third quarter worth $7,915,000. Suvretta Capital Management LLC acquired a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth $7,030,000. Acuta Capital Partners LLC acquired a new position in shares of Whitehawk Therapeutics during the third quarter worth about $6,480,000. Avoro Capital Advisors LLC purchased a new position in Whitehawk Therapeutics during the third quarter worth about $5,414,000. Finally, Yu Fan purchased a new position in Whitehawk Therapeutics during the third quarter worth about $3,933,000. 52.08% of the stock is owned by hedge funds and other institutional investors. About Whitehawk Therapeutics (Get Free Report)Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.See AlsoFive stocks we like better than Whitehawk TherapeuticsThe Fed Pivot Signal Smart Money’s Been Waiting ForDo not delete, read immediately“$6.6 Trillion Of Customer Bank Deposits At Risk”Terrifying reason Trump killed the U.S. penny?$100 Trillion “AI Metal” Found in American Ghost TownThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Whitehawk Therapeutics Right Now?Before you consider Whitehawk Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Whitehawk Therapeutics wasn't on the list.While Whitehawk Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here